Group | csf IL-2 | csf IL-4 | csf IL-5 | csf IL-8 | csf IL-10 | csf IL-12 | csf IL-13 | csf TNF | csf INFγ | serum IL-4 | serum IL-8 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
A | high responders | 19.30 (10) | 22.65 (10) | |||||||||
rest of sample | 16.00 (23) | 14.54 (23) | ||||||||||
U, P -value | n.s. | n.s. | n.s. | n.s. | 92.00, 0.027* | 58.50, 0.027* | ||||||
B | high responders | 22.80 (10) | 18.10 (10) | 19.70 (10) | 24.30 (10) | 22.70 (10) | 23.10 (10) | 19.50, 0.001 | 23.80 (10) | 21.50 (10) | 23.15 (10) | |
rest of sample | 13.64 (22) | 15.00 (21) | 14.24 (21) | 12.05 (21) | 12.81 (21) | 12.62 (21) | 11.76 (21) | 12.29 (22) | 14.23 (22) | 14.33 (23) | ||
U, P -value | 47.00, 0.008** | 84.00, 0.037* | 68.00, 0.042* | 22.00, <0.001*** | 38.00, 0.005** | 34.00, <0.001*** | 16.00, <0.001*** | 27.00, 0.001*** | 60.00, 0.016* | n.s. | 53.50, 0.016* | |
C | high responders | 24.00 (10) | 25.00 (10) | 25.15 (10) | 25.00 (10) | 23.35 (10) | 25.55 (10) | 20.65 (10) | ||||
rest of sample | 13.09 (22) | 12.64 (22) | 12.57 (22) | 12.64 (22) | 13.39 (22) | 12.39 (22) | 14.61 (22) | |||||
U, P -value | 35.00, 0.002* | n.s. | 25.00, <0.001*** | 23.50, <0.001*** | 25.00, 0.001*** | 41.50, 0.001*** | n.s. | 68.50, 0.027 | n.s. | n.s. |